Today: 23 April 2026
Wesfarmers shares wobble after profit beat, as dividend date and consumer demand come into view
20 February 2026
2 mins read

Wesfarmers shares wobble after profit beat, as dividend date and consumer demand come into view

Sydney, Feb 20, 2026, 17:32 AEDT — Market’s done for the day.

  • Wesfarmers dropped 0.3% to finish at A$83.99 on Friday, following a sharp drop the day before.
  • The group bumped up its interim profit and hiked the interim dividend to A$1.02 per share.
  • Planned price cuts, margins, and the dividend schedule set for next week are drawing investors’ attention.

Wesfarmers closed out Friday at A$83.99, slipping another 0.3%. That adds to Thursday’s 5.6% tumble after results hit. Shares are set to go ex-dividend Feb. 24.

Wesfarmers stands out as a key barometer for the state of Australian households. Bunnings and Kmart, right at the heart of that narrative, have started trading as if the market expects “good businesses, harder year”.

The timing? Right in the middle of reporting season, when investors tend to react sharply to any whiff of slowing growth. Wesfarmers delivered steady first-half results—solid enough. But there’s not much reassurance looking ahead to the coming six months.

Wesfarmers posted a first-half net profit after tax of A$1.6 billion, a 9.3% increase, and announced a fully franked interim dividend of A$1.02 per share—so shareholders get the benefit of Australian tax credits. Kmart Group’s EBIT came in at A$733 million for the period. WesCEF, meanwhile, lifted its EBIT to A$210 million. The company’s dividend record date falls on Feb. 25, with payment set for March 31.

Even so, management took a reserved stance looking ahead. CEO Rob Scott highlighted patchy consumer spending and flagged that inflation was “impacting the cost of living,” adding that uncertainty over inflation and interest rates was weighing on sentiment. To hang onto customers, the group pushed through price cuts—offset in part by productivity gains and broader use of artificial intelligence. Brokers, meanwhile, noted the profit beat was propped up more by lithium exposure than by the core retail operation. https://www.reuters.com/business/australia…

Analysts zeroed in on valuation on Friday. UBS stuck with Neutral, targeting A$90. Morgans, holding its Trim rating, nudged its price target up to A$80.50. Over at JPMorgan, analysts left their Underweight in place and set a A$72 target, saying the result reflected strength in lower-quality segments, not the core.

Wesfarmers CFO Anthony Gianotti told reporters in a separate Friday interview that the company’s priority is still productivity—he wants to “reinvest[ing] productivity gains back into delivering lower prices.” Lithium, he said, is “just at the start of the… journey.” Gianotti also flagged fresh partnerships with Microsoft and Google, moves meant to speed up Wesfarmers’ push into AI. https://www.livewiremarkets.com/wires/stro…

Traders now want to see if price investments can hold up volumes without putting too much squeeze on margins. If discounting starts to look more like a battle than a strategy, the stock could stay under pressure.

If consumers pull back even more, retailers could see margins squeezed, and lithium profits might lose steam right when the market is hungry for clear signs of retail strength. Stubborn cost inflation, or rates refusing to budge lower, would put Wesfarmers’ “resilience” valuation under real pressure.

Stock Market Today

  • ARS Pharmaceuticals (SPRY) Jumps 7.1% on FDA Nod and Strong Earnings Outlook
    April 23, 2026, 10:39 AM EDT. ARS Pharmaceuticals shares surged 7.1% to $8.40 on higher investor interest following FDA approval of expanded use for its lead product, neffy. The drop in minimum age restrictions allows its use in children and adults weighing at least 33 lbs for severe allergic reactions. The company anticipates a quarterly loss of 50 cents per share, improving 42.9% year-over-year, with revenues expected to increase 180.4% to $22.35 million. Earnings estimate revisions have been positive, with a 4.6% rise in the past month, often a signal of short-term price gains. ARS carries a Zacks Rank #3 (Hold). Aurinia Pharmaceuticals, a peer in the medical-drugs sector, also rose 3.8% recently amid improving earnings forecasts.

Latest article

Google Stock Gets Fresh AI Catalyst as Alphabet Unveils Agents, Chips Before Earnings

Google Stock Gets Fresh AI Catalyst as Alphabet Unveils Agents, Chips Before Earnings

23 April 2026
Alphabet Class A shares traded near $340 Thursday morning, valuing the company at about $4.1 trillion after Google unveiled new enterprise AI software and custom chips at its Cloud Next event. The announcements come days before Alphabet reports first-quarter earnings on April 29, with investors watching for signs that heavy AI and cloud spending will drive revenue growth.
FirstEnergy Ohio Rate Plan Could Add $4-$5 a Month to Bills as May 22 Filing Nears

FirstEnergy Ohio Rate Plan Could Add $4-$5 a Month to Bills as May 22 Filing Nears

23 April 2026
FirstEnergy’s Ohio utilities will file a three-year rate plan with state regulators by May 22, seeking to fund $800 million annually in grid upgrades and $83 million for tree trimming. The plan would raise monthly bills for typical 1,000-kWh households by $4.26 to $5.30 if approved. The filing follows recent rate cases by AES Ohio and AEP Ohio under the new House Bill 15 regime.
Salesforce stock slips as Momentum deal and UBS target cut put CRM in focus ahead of Feb. 25 earnings
Previous Story

Salesforce stock slips as Momentum deal and UBS target cut put CRM in focus ahead of Feb. 25 earnings

OCBC share price today: OCBC stock closes higher ahead of Feb 25 results
Next Story

OCBC share price today: OCBC stock closes higher ahead of Feb 25 results

Go toTop